Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.

19 Mar 2010

Working rotating shifts may increase risk of developing IBS and abdominal pain

Nurses participating in shift work, especially those working rotating shifts, face a significantly increased risk of developing Irritable Bowel Syndrome (IBS) and abdominal pain compared to those working a standard day-time schedule, according to research published in the American Journal of Gastroenterology.

19 Mar 2010

Hypnotherapy and probiotics effective for reducing IBS symptoms

Hypnotherapy seems to be very effective for easing the distressing symptoms of irritable bowel syndrome (IBS), and in a goodly proportion of cases, clears up symptoms altogether, reveal experts during a wide ranging discussion of the condition in a Frontline Gastroenterology podcast.

18 Mar 2010

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the pricing of a public offering and concurrent private placement of its common stock in which the aggregate net proceeds to Lexicon will be approximately $165.0 million. The public offering consists of 87,717,391 shares of its common stock at a public offering price of $1.15 per share.

16 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

New study suggests rising childhood obesity is linked to food allergies

First Lady Michelle Obama’s “Let’s Move” Campaign tells us that about 32 percent of children and teens (or 25 million) are obese or overweight. It revealed those extra pounds put them at greater risk of developing debilitating and costly diseases including diabetes, high blood pressure and high cholesterol and may also cause them to lead a two to five year shorter life than their parents

10 Mar 2010

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.

8 Mar 2010

Neurocrine Biosciences to sell common stock shares

Neurocrine Biosciences, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is the sole book-running manager for this offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

5 Mar 2010

Colonoscopy screening recommended for people with family history of colon cancer

A family history of colon cancer, also known as colorectal cancer or CRC, puts people at higher than average risk for developing the disease.

2 Mar 2010

NIH panel proposes multiple management strategies for lactose intolerant individuals

Lactose intolerance is a real and important clinical syndrome, but quantifying its public health burden is challenging. An NIH Consensus Development panel was convened this week to assess the available evidence on lactose intolerance and health across the age spectrum and across racial and ethnic groups.

25 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Tioga Pharmaceuticals, Inc. today announced the closing of an $18 million equity financing. Current investors Forward Ventures, New Leaf Venture Partners and BB Biotech Ventures were joined by new investor Genesys Capital Partners.

17 Feb 2010

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood’s Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).

17 Feb 2010

Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

Exagen Diagnostics, Inc., a molecular diagnostics laboratory that discovers, develops and markets proprietary genomic tests, today announced an exclusive sales and marketing agreement with EndoChoice, Inc. to promote its diagnostic services to gastroenterologists throughout the United States.

17 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010

New research may help adopt acupuncture as a treatment option for NHS patients

Important new research about the effects of acupuncture on the brain may provide an understanding of the complex mechanisms of acupuncture and could lead to a wider acceptability of the treatment.

4 Feb 2010

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

Quintiles today announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany. Under the alliance, Quintiles will execute a comprehensive commercial sales effort for the product launch and provide additional services in consulting, market access, market intelligence and analytics, regulatory and post-marketing pharmacovigilance.

29 Jan 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Working rotating shifts may increase risk of developing IBS and abdominal pain

Hypnotherapy and probiotics effective for reducing IBS symptoms

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

New study suggests rising childhood obesity is linked to food allergies

Lexicon Pharmaceuticals proposes $95 million underwritten public offering of common stock

Neurocrine Biosciences to sell common stock shares

Colonoscopy screening recommended for people with family history of colon cancer

NIH panel proposes multiple management strategies for lactose intolerant individuals

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

Exagen Diagnostics, EndoChoice announce agreement for promoting diagnostic services to U.S. gastroenterologists

TI commences Phase IIa clinical trial for its lead molecule in CDH

New research may help adopt acupuncture as a treatment option for NHS patients

Quintiles announces strategic alliance with Movetis NV for commercialization of Resolor

DNA variations in genes increase risk of developing PI-IBS

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Irritable Bowel Syndrome News and Research

Latest Irritable Bowel Syndrome News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in